Related Experiment Video
Updated: Jul 9, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide in multiple myeloma
Sheeba K Thomas1, Tiffany A Richards, Donna M Weber
1The University of Texas M.D. Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe BLVD, Box 429, Houston, TX 77030, USA.
Best Practice & Research. Clinical Haematology
|December 12, 2007
Summary
Lenalidomide offers improved efficacy and safety for multiple myeloma treatment compared to older regimens. This thalidomide analog shows significant clinical activity in newly diagnosed and relapsed patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment historically relied on melphalan-prednisone and VAD regimens.
- These older treatments yielded limited response rates (45-55%) and complete remission rates (up to 10%).
- Emerging therapies like thalidomide and bortezomib improved response rates but introduced side effects.
Purpose of the Study:
- To evaluate the role of lenalidomide, a thalidomide analog, in managing multiple myeloma.
- To assess lenalidomide's efficacy and toxicity profile compared to existing treatments.
- To describe lenalidomide's application in various patient populations, including newly diagnosed and relapsed/refractory cases.
Main Methods:
- Review of clinical data on lenalidomide in multiple myeloma patients.
- Analysis of treatment outcomes including response rates and complete remission rates.
- Assessment of lenalidomide's side effect profile.
Main Results:
- Lenalidomide-based combinations achieve higher response rates (85-95%) and complete remission rates (up to 25%) compared to older regimens.
- Lenalidomide demonstrates significant clinical activity in patients with multiple myeloma.
- Lenalidomide was developed to improve upon the efficacy and toxicity of thalidomide.
Conclusions:
- Lenalidomide represents a significant advancement in multiple myeloma therapy.
- It offers a more favorable efficacy and toxicity profile for patients.
- Lenalidomide is a valuable therapeutic option for newly diagnosed, relapsed/refractory multiple myeloma, and primary amyloidosis.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...